论文部分内容阅读
胚胎发育及癌变过程中,人或动物细胞癌发育基因产物——癌胚蛋白(oncodevelopmentalproteins)的量与质均具有一定的相似性。正常与胚胎或癌细胞之间的差异,仅在于前者的癌基因表达被抑制,后者去抑制。这一基本概念上的突破推动了生物学及医学的深入研究,为癌症及其它胎儿先天性疾患的诊断奠定了基础。当前在临床上AFP除已被确认为一种特异性较强的肿瘤标志物,同时从基础上也研究了它的胚胎发育及癌变过程中基因表达、生物合成和分子构型的演变。本文着重概述AFP分子变异体的理化和生物学特性及其临床意义
During embryonic development and carcinogenesis, the quantity and quality of the gene product of human or animal cell carcinoma development-oncoprotein (oncodevelopmental proteins) have some similarities. The only difference between normal and embryonic or cancer cells is that the former oncogene expression is inhibited and the latter is de-suppressed. This basic conceptual breakthrough led to in-depth research in biology and medicine, and laid the foundation for the diagnosis of cancer and other fetal congenital disorders. Currently, AFP has been clinically recognized as a highly specific tumor marker, and at the same time, its gene expression, biosynthesis and molecular configuration evolution during embryonic development and carcinogenesis have also been studied. This article highlights the physicochemical and biological properties of AFP molecular variants and their clinical implications